Welcome to Novo Nordisk Science Hub

Are you a healthcare professional?

EASD 2026 28 September - 2 October 2026

Effect of CagriSema on bone biomarkers in participants with inadequately controlled type 2 diabetes: REIMAGINE 2​

Sorry! It looks like the page you are trying to access contains materials that are still under embargo. Please come back and check again later.
Keywords
Diabetes
Congress short oral presentation
Amylin
CagriSema
PHASE 3 (RCT)